Cockcroft D W, Murdock K Y, Berscheid B A, Gore B P
Royal University Hospital, Saskatoon, Saskatchewan, Canada.
J Allergy Clin Immunol. 1992 Jan;89(1 Pt 1):23-30. doi: 10.1016/s0091-6749(05)80037-5.
Histamine provocative concentration causing a 20% drop in FEV1 (PC20) was measured in 500, randomly selected, young (20 to 29 years) university students. Participation was 500/619, or 81%. In this population, by a research assistant-administered questionnaire, we identified 17 subjects with current asthma, 16 with asthma only on allergen exposure, 19 with past (more than 1 year ago) asthma, 158 with rhinitis (77 atopic and 81 nonatopic subjects), and 290 subjects with neither asthma nor rhinitis. Histamine airway hyperresponsiveness (PC20 less than or equal to 8 mg/ml) was observed in 58 subjects and included the 17 subjects with current asthma, 6/16 with asthma only on allergen exposure, 2/19 subjects with previous asthma, 20/158 with rhinitis, and 13/290 subjects with neither asthma nor rhinitis. With "current symptomatic asthma" as the diagnosis and PC20 less than or equal to 8 mg/ml as the positive test, the sensitivity was 100%, the specificity was 93%, and the negative predictive value was 100%; the positive predictive value (for current symptoms of asthma) was only 29%. The strength of this test with a cutoff of 8 mg/ml is the high sensitivity, indicating that a PC20 greater than 8 mg/ml is likely to indicate that current asthma is not present. The weakness is the failure to predict current symptoms of asthma. As the cutoff is lowered, for example, to PC20, 1 mg/ml, the sensitivity falls to less than 50% and the positive predictive value approaches 100%. These data indicate that a PC20 greater than 8 (or 16) mg/ml rules out current asthma in most instances, whereas a PC20 less than 1 mg/ml is almost diagnostic of current asthma. Values between 1 and 8 mg/ml are intermediate in these regards.
对500名随机挑选的20至29岁年轻大学生测量了引起第一秒用力呼气容积(FEV1)下降20%的组胺激发浓度(PC20)。参与率为500/619,即81%。在这一人群中,通过研究助理发放的问卷,我们确定了17名患有当前哮喘的受试者、16名仅在接触过敏原时出现哮喘的受试者、19名曾患(超过1年前)哮喘的受试者、158名患有鼻炎的受试者(77名特应性和81名非特应性受试者)以及290名既无哮喘也无鼻炎的受试者。58名受试者观察到组胺气道高反应性(PC20小于或等于8mg/ml),包括17名患有当前哮喘的受试者、16名仅在接触过敏原时出现哮喘的受试者中的6名、19名曾患哮喘的受试者中的2名、158名患有鼻炎的受试者中的20名以及290名既无哮喘也无鼻炎的受试者中的13名。以“当前症状性哮喘”为诊断标准,PC20小于或等于8mg/ml为阳性检测结果,其敏感性为100%,特异性为93%,阴性预测值为100%;阳性预测值(针对当前哮喘症状)仅为29%。该检测以8mg/ml为临界值的优势在于敏感性高,表明PC20大于8mg/ml可能表明当前不存在哮喘。其劣势在于无法预测当前哮喘症状。随着临界值降低,例如降至PC20为1mg/ml时,敏感性降至50%以下,阳性预测值接近100%。这些数据表明,在大多数情况下,PC20大于8(或16)mg/ml可排除当前哮喘,而PC20小于1mg/ml几乎可诊断当前哮喘。在这些方面,1至8mg/ml之间的值处于中间状态。